CNS Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CNSP CNS Pharmaceuticals Inc
SMTC Semtech Corp
EU enCore Energy Corp
CJET Chijet Motor Co Inc
LAKE Lakeland Industries Inc
JWEL Jowell Global Ltd
SMAR Smartsheet Inc
FOXA Fox Corp
SCVFF Scotch Creek Ventures Inc
VEDU Visionary Education Technology Holdings Group Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Price
Delayed
$2.57
Day's Change
-0.115 (-4.29%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.72
Day's Low
2.48
Volume
(Light)

Today's volume of 90,065 shares is on pace to be much lighter than CNSP's 10-day average volume of 1,263,378 shares.

90,065

Regency Centers Corp. Stock Outperforms Market On Strong Trading Day

5:20 pm ET March 27, 2023 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Regency Centers Corp. (REG) inched 0.27% higher to $58.50 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.16% to 3,977.53 and the Dow Jones Industrial Average rising 0.60% to 32,432.08. This was the stock's third consecutive day of gains. Regency Centers Corp. closed $14.91 short of its 52-week high ($73.41), which the company reached on April 21st.

The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Realty Income Corp. (O) fell 0.54% to $60.71, Kimco Realty Corp. (KIM) rose 0.89% to $18.17, and Federal Realty Investment Trust (FRT) rose 0.01% to $92.52. Trading volume (1.1 M) eclipsed its 50-day average volume of 985,828.

Data source: Dow Jones Market Data, FactSet. Data compiled March 27, 2023.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

	

(END) Dow Jones Newswires

March 27, 2023 17:20 ET (21:20 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.